Physician profile
Michael T Dresdner
NPI 1962567172
$2,789.68
in general payments reported to CMS, 2019-2025
34 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $589 · 2021: $222 · 2022: $225 · 2023: $467 · 2024: $273 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.89 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $633.19 | 2019-2025 | Slynd |
| Celularity INC. | $616.00 | 2019-2020 | |
| Abbvie INC. | $298.14 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $281.23 | 2023-2025 | Veozah |
| Lupin INC. | $121.13 | 2019-2021 | |
| Therapeuticsmd, INC. | $99.12 | 2019-2021 | |
| Avion Pharmaceuticals | $57.08 | 2019-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $55.28 | 2025 | |
| Scynexis, INC. | $54.24 | 2022 | |
| Allergan, INC. | $50.05 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $43.99 | 2019 | |
| Axonics, INC. | $39.55 | 2023 | Axonics, Bulkamid |
| Lilly USA, LLC | $36.60 | 2025 | Mounjaro |
| Hologic Sales and Service, LLC | $36.22 | 2021-2024 | Aptima |
| Novo Nordisk INC | $33.14 | 2025 | Ozempic |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.88 | 2023 | |
| Mycovia Pharmaceuticals, INC. | $28.00 | 2022-2023 | Vivjoa |
| Dysis Medical, INC. | $27.67 | 2020 | |
| Becton, Dickinson and Company | $26.28 | 2021-2022 | |
| Evofem Biosciences, INC. | $25.97 | 2021-2024 | |
| Coopersurgical, INC. | $25.61 | 2022 | |
| Mission Pharmacal Company | $20.88 | 2020 | |
| Organon LLC | $20.81 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2025 | |
| Roche Diagnostics Corporation | $17.99 | 2019 | |
| Agile Therapeutics, INC. | $14.34 | 2022 | |
| Merck Sharp & Dohme LLC | $14.06 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.60 | 2023 | Exparel |
| Minerva Surgical, INC | $12.86 | 2020 | |
| Novum Pharma, LLC | $12.53 | 2019 | |
| Millicent US INC | $12.01 | 2019 | |
| Horizon Therapeutics Plc | $11.89 | 2022 | |
| Alydia Health | $1.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dresdner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.